tirzepatide 2.5 dose (Mounjaro) for the Treatment of Type 2 Diabetes Mellitus MOUNJARO 2.5 MG / 0.5
Description
Do not skip dose tiers
After 72 weeks of treatment: 5 mg dose: 15.0% mean body weight reduction 10 mg dose: 19.5% mean body weight reduction 15 mg dose: 20.9% mean body weight reduction Placebo: 3.1% mean body weight reduction Among participants receiving 15 mg, approximately 57% achieved at least 20% weight loss
Similar content being viewed by others 1 Introduction/background: role of incretins in diabetes and weight Incretins are endogenous proteins responsible for multiple bodily functions including the moderation of blood glucose and the feelings of satiety [1]
This works well for higher doses (10 to 15 mg per week) where you want smaller injection volumes
A 7.5mg dose requires 0.94mL
That equation is only true at 10 mg/mL
